They always provide a sales update for the AGM, so we will likely get more results some time in November. However there is no obligation to report outside of the normal reporting periods, regardless of how strong the numbers are. I do think this half should be more eventful than the prior half news wise though, we already know we have the August audited results, AGM results and the bullish reimbursement news coming. Plus I'd be expecting additional approvals and perhaps even some trial results as well. Then there are all the potential unknown announcements (eg takeovers, 2RT partnership etc) to look forward to.
They always provide a sales update for the AGM, so we will...
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
0.005(3.33%) |
Mkt cap ! $35.50M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 15.5¢ | 15.5¢ | $13.41K | 86.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 581087 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 150000 | 2 |
View Market Depth
| Last trade - 13.10pm 15/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |